ABBV vs AMGN Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie and Amgen are both major biopharmaceutical companies managing the transition away from legacy blockbuster products facing biosimilar competition, but AbbVie has already demonstrated strong replacement growth from its newer immunology therapies, while Amgen is working to grow its obesity drug pipeline alongside its established oncology and inflammation portfolio.
AbbVie offers exposure to a demonstrated post-Humira growth transition backed by newer immunology therapies, while Amgen offers exposure to an established biotechnology platform with emerging obesity drug pipeline potential. Consider whether you prefer AbbVie's already-proven transition or Amgen's earlier-stage obesity pipeline opportunity.
ABBV holds the edge across 3 of 5 key metrics in this comparison. AMGN leads on both 1-year return (+57.74%) and forward P/E quality (15.46x vs 15.79x for ABBV), a relatively favorable combination of momentum and valuation. ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+7.85%) than for AMGN (+2.83%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a demonstrated post-Humira growth transition through newer immunology therapies
- Value diversification across immunology, oncology, neuroscience, and aesthetics
- Believe a long dividend growth track record reflects durable capital allocation discipline
- Prefer a company that has already shown successful replacement of lost legacy product revenue
- Want exposure to an established biotechnology platform across oncology, inflammation, and bone health
- Believe the emerging obesity drug pipeline offers meaningful long-term growth potential
- Are comfortable with ongoing biosimilar competition pressuring legacy product revenue
- See value in a company with deep biologics manufacturing and development expertise
| Metric | ABBV | AMGN |
|---|---|---|
| AI scorei | 63.0 | 52.6 |
| AI ranki | #174 | #413 |
| Latest closei | $290.79 | $460.73 |
| 1M returni | +10.44% | +8.76% |
| 3M returni | +12.97% | +18.86% |
| 6M returni | +37.61% | +33.06% |
| 1Y returni | +27.80% | +57.74% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | AMGN |
|---|---|---|
| 1Y ago | $12.92K (+29.2%) started 2025-10-29 | $15.79K (+57.9%) started 2025-10-29 |
| 5Y ago | $33.31K (+233.1%) started 2021-11-01 | $28.13K (+181.3%) started 2021-11-01 |
| 10Y ago | $115.52K (+1055.2%) started 2016-10-31 | $57.23K (+472.3%) started 2016-10-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | AMGN |
|---|---|---|
| Market capi | $454.36B | $204.01B |
| Trailing P/Ei | 72.43 | 23.42 |
| Forward P/Ei | 15.79 | 15.46 |
| Price/Salesi | 5.85 | 4.57 |
| EV/Revenuei | 8.06 | 6.49 |
| Analyst targeti | $277.31 | $388.03 |
| Target upsidei | +7.85% | +2.83% |
| Metric | ABBV | AMGN |
|---|---|---|
| Revenue growthi | 10.20% | 9.50% |
| Earnings growthi | 290.40% | 64.90% |
| EPS growthi | +290.40% | +64.90% |
| FCF margini | +26.20% | +22.69% |
| Operating margini | 40.03% | 35.55% |
| Profit margini | 9.80% | 22.95% |
| ROIC proxyi | 6225.00% | 91.47% |
| Return on equityi | 6225.00% | 91.47% |
| Dividend yieldi | 2.69% | 2.64% |
| Payout ratioi | 190.40% | 60.87% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.28 | 0.43 |
| Debt/equityi | 4789.60 | 490.28 |
| Current ratioi | 0.81 | 1.37 |
| Quick ratioi | 0.49 | 0.95 |
Over the past year, ABBV and AMGN have moved moderately in the same direction (correlation of 0.47), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | AMGN |
|---|---|---|---|
| 1Y | Growthi | +29.16% | +57.91% |
| CAGRi | +29.21% | +58.01% | |
| Volatilityi | 25.83% | 29.63% | |
| Sharpe ratioi | 0.95 | 1.55 | |
| Sortino ratioi | 1.44 | 2.44 | |
| Max drawdowni | 16.46% | 16.57% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 5.12% | 5.96% | |
| Ulcer Indexi | 6.62% | 7.67% | |
| Max daily dropi | 5.20% | 10.08% | |
| Max wkly dropi | 8.49% | 15.03% | |
| 5Y | Growthi | +189.11% | +147.65% |
| CAGRi | +23.70% | +19.92% | |
| Volatilityi | 23.38% | 24.94% | |
| Sharpe ratioi | 0.84 | 0.68 | |
| Sortino ratioi | 1.17 | 1.02 | |
| Max drawdowni | 21.92% | 24.86% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 8.02% | 8.19% | |
| Ulcer Indexi | 9.98% | 10.34% | |
| Max daily dropi | 12.57% | 10.08% | |
| Max wkly dropi | 17.30% | 15.03% | |
| 10Y | Growthi | +648.80% | +324.48% |
| CAGRi | +22.32% | +15.56% | |
| Volatilityi | 25.95% | 25.16% | |
| Sharpe ratioi | 0.74 | 0.52 | |
| Sortino ratioi | 1.03 | 0.78 | |
| Max drawdowni | 45.09% | 24.86% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 11.46% | 7.88% | |
| Ulcer Indexi | 15.55% | 9.76% | |
| Max daily dropi | 16.25% | 10.08% | |
| Max wkly dropi | 19.39% | 15.03% |
| Category | ABBV | AMGN |
|---|---|---|
| Company | AbbVie Inc. | Amgen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | A global biopharmaceutical company with a strong immunology franchise built around newer therapies developed to succeed its long-dominant Humira product, alongside oncology, neuroscience, and aesthetics businesses. | A global biotechnology company with an established portfolio spanning oncology, inflammation, and bone health treatments, alongside a growing obesity drug pipeline, working to manage biosimilar competition on legacy products. |
| Investor focus | Newer immunology drug revenue growth as replacements for Humira following biosimilar competition, oncology and neuroscience pipeline progress, and dividend growth track record. | Growth of newer drugs including obesity pipeline candidates, biosimilar competition trends on legacy products, and dividend sustainability given the maturity of its established portfolio. |
- Newer immunology therapies have shown strong growth momentum in replacing revenue lost to Humira biosimilar competition
- Diversified portfolio spanning immunology, oncology, neuroscience, and aesthetics reduces dependence on any single franchise
- Long track record of dividend growth reflects a shareholder-focused capital allocation approach
- Established biotechnology platform with deep expertise across oncology, inflammation, and bone health treatment categories
- Emerging obesity drug pipeline provides exposure to one of the fastest-growing pharmaceutical categories
- Long operating history and manufacturing scale support efficient production and distribution of biologic therapies
- Continues to manage the transition away from Humira as biosimilar competition erodes its historically dominant product
- Newer immunology drugs face their own future competitive and patent-related risks over time
- Aesthetics business is sensitive to discretionary consumer spending trends
- Legacy biologic products face ongoing biosimilar competition that pressures revenue over time
- Obesity drug pipeline remains in earlier competitive stages relative to some established rivals in that category
- Biotechnology manufacturing and pipeline development require sustained, significant research and development investment
Compare more than two at a time
This page is a fixed writeup on ABBV and AMGN. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ABBV and AMGN, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.